Canadian Vaccine Corp (CVC) undertook a research and development project in 2015, As of March 1 of that year, management concluded that the project had met the requirements for the capitalization of development costs. For the remainder of 2015 and 2016, the company capitalized $4.3 million of development costs for the project In 2017, CVC began amortizing the development cost over the estimated useful life of 10 years, beginning with a full year of amortization in 2017. In 2020, the company engaged a public accounting firm to conduct an audit of its financial statements. The auditors concluded that the development cost did not meet the criteria for capitalization since CVC, at the time, did not demonstrate that the company had sufficient financial resources to complete the project. CVC eventually agreed with the auditors and the company had not yet recorded any amortization for 2020 when it agreed to correct the error. The company's tax rate is 30%. Required: Record the journal entries necessary to correct CVC's accounts. Include the effect of income taxes